| paclitaxel / Generic mfg. |
ACTRN12607000043437: Weekly Carboplatin and Taxol with concurrent radiotherapy for locally advanced non small cell lung : Predictive factors for completion of treatment. |
|
|
| Terminated | 4 | 45 | | | South Eastern Illawarra Area Health service, Bristol Myers Squibb | Non Small Cell Lung Cancer (NSCLC) | | | | |
| Unknown status | 4 | 77 | Europe | sirolimus drug eluting coronary stent Cypher™ (Cordis Corp, Johnson & Johnson Co), Cypher™ (Cordis Corp, Johnson & Johnson Co) DES, paclitaxel polymer drug eluting stent Taxus Libertè™ (Boston Scientific, Natick MS), Taxus Libertè™ (Boston Scientific, Natick MS) DES, zotarolimus drug eluting coronary stent Endeavor™ (Medtronic, Santa Rosa, CA), Endeavor™ (Medtronic, Santa Rosa, CA) DES, Libertè bare metal coronary stent Libertè™ BMS(Boston Scientific, Natick, MS), Libertè™ BMS(Boston Scientific, Natick, MS) | A.O. Ospedale Papa Giovanni XXIII, Case Western Reserve University, Medtronic Vascular, Boston Scientific Corporation | Coronary Artery Disease | 06/08 | 12/08 | | |
| Completed | 4 | 16 | RoW | Liposomal paclitaxel, Paclitaxel | Shandong Luye Pharmaceutical Co., Ltd., Nanjing Sike Pharmaceutical Co., Ltd. | Cancer | 10/08 | 10/08 | | |
NCT00686322: Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC) |
|
|
| Completed | 4 | 6 | RoW | Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy), paclitaxel, cisplatin | Taipei Veterans General Hospital, Taiwan | Non-small-cell Lung Cancer | 04/09 | 10/09 | | |
NCT00912639: A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer |
|
|
| Unknown status | 4 | 90 | RoW | Paclitaxel loaded Polymeric micelle, Genexol-PM® | Korean Breast Cancer Study Group | Recurrent Breast Cancer | 05/10 | 05/11 | | |
ChiCTR-TRC-09000573: Comparative Study of High-Dose versus Standard-dose Chemotherapy with Docetaxel and Thiotepa regimen for Metastatic Breast Cancer |
|
|
| Completed | 4 | 300 | | paclitaxel 175mg/m2 or docetaxel 120mg/m2 with thiotepa 175mg/m2 ;paclitaxel 175mg/m2 or docetaxel 75mg/m2 withthiotepa 75mg/m2 | Beijing Cancer Hospital & Institute, Peking University School of Oncology; Level of the institution：, self funded | Metastatic Breast Cancer | | | | |
ChiCTR-TRC-10000794: Treatment of HER-2 negative breast cancer by neoadjuvant chemotherapy combined with WTPA |
|
|
| Completed | 4 | 60 | | Neoadjuvant chemotherapy (Paclitaxel 80 mg/m2, IV, d1, d8, d15, plus Carboplatin AUC=2, IV, d1, d8, d15, every 28 days for 4 cycles) + WTPA (1 ml, sc, qod, from the start of chemotherapy until 3 day before surgery) ;Neoadjuvant chemotherapy (Paclitaxel 80 mg/m2, IV, d1, d8, d15, plus Carboplatin AUC=2, IV, d1, d8, d15, every 28 days for 4 cycles) + Placebo (1 ml, sc, qod, from the start of chemotherapy until 3 day before surgery) | Cancer Hospital, Fudan University; Beijing Wanter Bio-pharmaceutical Co. Ltd, Beijing Wanter Bio-pharmaceutical Co. Ltd | HER-2 negative locally advanced breast cancer | | | | |
ChiCTR-TRC-10001187: Prospective, open, multicentre clinical trial (phase II) of Endostar(recombinant human endostatin) on combined radiotherapy and chemotherapy for esophageal cancer |
|
|
| Completed | 4 | 60 | | Endostar: 7.5mg/m2, D1-D14, D21-35; for 2 cycles; Paclitaxel Injection: 175mg/m2, D1; DDP: 75-90mg/m2, D1; E=6MV, GTV-P: 60-66Gy/30-33every time/6~7w (2Gy-2.1/every time), CTVN-P: 51Gy/30 (1.7Gy/every time) ;Paclitaxel Injection: 175mg/m2, D1; DDP: 75-90mg/m2, D1; E=6MV, GTV-P: 60-66Gy/30-33every time/6-7w (2Gy-2.1/every time), CTVN-P: 51Gy/30 (1.7Gy/every time) | Fujian Provincial Tumor Hospital; Jiangsu Simcere pharmaceutical Co.Ltd, Jiangsu Simcere pharmaceutical Co.Ltd | ⅡB, III, IV esophageal cancer | | | | |
NCT01156961: A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX) |
|
|
| Withdrawn | 4 | 0 | RoW | bevacizumab [Avastin], paclitaxel | Hoffmann-La Roche | Breast Cancer | 12/12 | 12/12 | | |
ChiCTR-TRC-11001333: Aoxianda (Nedaplati) combined with Paclitaxel for treatment of epithelial ovarian cancer: a randomized, multicenter, parallel-controlled clinical trial |
|
|
| Completed | 4 | 200 | | Day 1: Paclitaxel 135 mg/m2; Day 2: Carboplati AUC=5; repeat every 3 wks for 6 cycles. ;Day 1: Paclitaxel 135 mg/m2; Day 2: Aoxianda 80mg/m2; repeat every 3 wks for 6 cycles. | 1st people hospital of Shanghai; Jiangsu Aosaikang Pharmaceutical Co., Ltd., Jiangsu Aosaikang Pharmaceutical Co., Ltd. | epithelial ovarian cancer | | | | |
ChiCTR-TRC-11001327: Randomized Phase IV Trial of Molecular Analysis-Directed Individualized Therapy in Advanced Non-Small-Cell Lung Cancer |
|
|
| Completed | 4 | 210 | | Vinorelbine +cisplatin ;Etoposide+cisplatin ;Erlotinib ;Vinorelbine +cisplatin of Gemcitabine+cisplatin or Paclitaxel+cisplatin ;Vinorelbine +cisplatin of Gemcitabine+cisplatin or Paclitaxel+cisplatin ;Gemcitabine+cisplatin | First Affiliated Hospital Bengbu Medical College; First Affiliated Hospital of Anhui Traditional Chinese Medical College, Health Department of Anhui Province | Non-Small-Cell Lung Cancer | | | | |
ChiCTR-OCH-11001856: A clinic study to assess the clinical efficacy and immunological effects of gefitinib and standard chemotherapy in malignant pleural effusion caused by advanced non-small cell lung cancer |
|
|
| Completed | 4 | 60 | | administer gefitinib orally ;administer carboplatin/paclitaxel intravenously | Department of Respiratory Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Department of Respiratory Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self funded | malignant pleural effusion caused by advanced non-small cell lung cancer | | | | |
ChiCTR-TRC-12002363: Clinical study of recombinant human endostatin in deferent time combined with paclitaxel and cisplatin in treatment of advanced none-small cell lung cancer |
|
|
| Completed | 4 | 90 | | human endostatin 7.5mg/m2 + Cisplatin 175mg/m2 +TP 80mg/m2 iv in day 1 and three weeks repeat and total two cycles ;human endostatin 7.5mg/m2 for 14 days +TP 80mg/m2 iv in day 1 and + Cisplatin 175mg/m2 in day 5 five weeks repeat and total two cycles ;TP 80mg/m2 iv in day 1 and + Cisplatin 175mg/m2 in day 5 five weeks repeat and total two cycles | Sichuan Province Luzhou Medical College affiliated Hospital; Simcere Pharmaceutical Company, Simcere Pharmaceutical Company | None Small Cell Lung Cancer | | | | |
NCT01301729: A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment |
|
|
| Completed | 4 | 32 | RoW | Docetaxel, Paclitaxel, Trastuzumab, Herceptin | Hoffmann-La Roche | Breast Cancer | 07/14 | 07/14 | | |
NCT01515228: Comparison of Cilotax Stent and Everolimus -Eluting Stent With Diabetes Mellitus (ESSENCE-DM III) |
|
|
| Completed | 4 | 291 | RoW | Xience Prime, everolimus-eluting stent, Cilotax stent, paclitaxel with cilostazol dual drug eluting stent | CHEOL WHAN LEE, MD, PhD., CardioVascular Research Foundation, Korea | Coronary Artery Disease | 12/14 | 01/15 | | |
PLC-GC, ChiCTR-TRC-12002105: An Open-label, Randomized Controlled Clinical Study: Paclitaxel Liposomes in Combination With Cisplatin Verus Gemcitabine Combined With Cisplatin in Treatment of III and IV stage NSCLC with regional lymph node metastasis |
|
|
| Completed | 4 | 120 | | paclitaxel liposome(135-175mg/m2 )+Saline(500ml) intravenous drip(3 hours);cisplatin(75mg/m2)+Saline(500ml) .intravenous drip. ;D1, 8: gemcitabine (1000mg/m2)＋Saline (100ml) intravenous dirp (in half an hour); D1: cisplatin (75mg/m2) + Saline (500ml) intravenous dirp. | Third Military Medical University; Southwest hospital, Southwest Hospital, Third Military Medical University, Chongqing | III and IV stage NSCLS with regional lymph node metastasis | | | | |
| Completed | 4 | 504 | RoW | kissing balloon, Sirolimus, Paclitaxel, Zotarolimus and Everolimus stents, without kissing balloon angioplasty "leave alone", sirolimus, zotarolimus, paclitaxel, and everolimus stents | Seung-Jung Park, CardioVascular Research Foundation, Korea | Coronary Artery Disease | 01/15 | 01/15 | | |
NCT01317615 / 2010-022273-34: RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation |
|
|
| Completed | 4 | 49 | Europe | RAD001, Everolimus, Paclitaxel, Carboplatin | Novartis Pharmaceuticals | Carcinoma, Large Cell, Neuroendocrine Tumors | 03/15 | 03/15 | | |
| Completed | 4 | 420 | RoW | Crush technique, Sirolimus, Paclitaxel, Zotarolimus and Everolimus stents, provisional T stenting | Seung-Jung Park, CardioVascular Research Foundation, Korea | Coronary Artery Disease | 06/15 | 06/15 | | |
ChiCTR-IPR-14005583: A mono-center, open, randomized phase II clinical trial to compare the efficacy of Paclitaxel plus Gemcitabine with Paclitaxel sequential Gemcitabine in the first-lined treatment of recurrent metastatic breast cancer |
|
|
| Recruiting | 4 | 120 | | paclitaxel plus gemcitabine ;paclitaxel sequential gemcitabine | Peking University Cancer Hospital & Institute; Fuling Central Hospital of Chongqing, Peking University Cancer Hospital (Beijing Cancer Hospital) | Breast Cancer | | | | |
| Completed | 4 | 49 | Europe | Bevacizumab, Avastin, Paclitaxel, Docetaxel | Hoffmann-La Roche | Breast Cancer | 12/15 | 12/15 | | |
2004-002429-37: A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high-risk endometrial carcinoma NSGO-EC-9501 Amendment 2. |
|
|
| Ongoing | 4 | 250 | Europe | AP (doxorubicin+cisplatin), TP (paclitaxel+carboplatin), TAP (paclitaxel+doxorubicin+cisplatin+filgrastim), TEC | Nordic Society for Gynecologic Oncology | Endometrial cancer stage I-III radically operated with high-risk factors (high-grade and deep myometrial infiltration, or serous or clear cell histology) that will receive adjuvant treatment with radiotherapy. | | | | |
2005-000403-33: Randomized clinical trial to evaluate the predictive accuracy of a geneexpression profile-based test to select patients for preoperativetaxane/anthracycline chemotherapy for stage I-III breast cancer |
|
|
| Ongoing | 4 | 60 | Europe | PACLITAXEL, FLUOROURACIL, CYCLOPHOSPHAMIDE, EPIRUBICIN, TAXOL, FLUOROURACILO FERRER FARMA, GENOXAL, PHARMORUBICIN, TAXOL, FLUOROURACILO FERRER FARMA, GENOXAL, PHARMORUBICIN | GRUPO ESPAÑOL DE INVESTIGACIÓN EN CÁNCER DE MAMA (GEICAM) | Patients with histologically confirmed stage I-III invasive carcinoma of the breastfor whom adjuvant chemotherapy is indicated. | | | | |
| Completed | 4 | 226 | US | TAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy, TCH chemotherapy, T + trastuzumab followed by CEF + trastuzumab, Dose dense AC followed by T + trastuzumab, Dose dense AC followed by T + trastuzumab + pertuzumab, PTH followed by dose dense AC of FEC | Agendia, University of South Florida, University of Miami, Morton Plant Mease Health Care, AdventHealth, Plano Cancer Center, Ohio State University Comprehensive Cancer Center, University of Oklahoma, University of South Alabama | Breast Cancer | 02/16 | 06/17 | | |
NCT02207361: Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer |
|
|
| Unknown status | 4 | 120 | RoW | Paclitaxel, Carboplatin, Paclitaxel, Epirubicin | Tianjin Medical University Cancer Institute and Hospital | Metastatic Breast Cancer | 11/16 | 12/16 | | |
2017-000641-44: Dose monitoring of commonly used cytostatic drugs for breast cancer |
|
|
| Ongoing | 4 | 250 | Europe | Cyclophosphamide, Epirubicin, Doxorubicin, Docetaxel, Paclitaxel, L01CD01, Concentrate and solvent for concentrate for solution for infusion, Concentrate and solvent for solution for infusion | Karolinska intitutet, Dept. of Oncology, Karolinska University Hospital | Newly diagnosed pre- or post-operative breast cancer, Breast cancer, Diseases [C] - Cancer [C04] | | | | |
| Completed | 4 | 240 | | weekly paclitaxel-epirubicin (PE) ;triweekly 5-uorouracil(5-FU)-epirubicin-cyclophos | West China Hospital of Sichuan University; Level of the institution：, Self-funding | the breast cancer | | | | |
2016-005029-36: Vergleich der Lebensqualität bei Patientinnen mit platinsensitivem wiederkehrenden Eierstock-, Eileiter- und Bachfellkrebs bei der Behandlung mit Trabectedin / PLD oder einer platinbasierten Standardtherapie - eine Kooperation der NOGGO und BNGO |
|
|
| Ongoing | 4 | 206 | Europe | Trabectedin, Pegylated liposomal Doxorubicin, Carboplatin, Gemzitabin, Placlitaxel, L01XA02, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for infusion, Yondelis 1 mg powder for solution for infusion, Caelyx, Carboplatin, Gemcitabin, Paclitaxel | NOGGO e.V., PharmaMar, S.A. | Ovarian Cancer, cancer of the ovaries, Diseases [C] - Cancer [C04] | | | | |
OTT15-04, NCT02688803: Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) |
|
|
| Completed | 4 | 2 | Canada | Dose dense AC-P, doxorubicin, cyclophosphamide, paclitaxel, Dose dense AC, FEC-D, 5-FU, docetaxel | Ottawa Hospital Research Institute | Breast Cancer | 10/17 | 10/17 | | |
NCT02513355: Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research |
|
|
| Unknown status | 4 | 400 | RoW | Endostar, Changchun marina, cisplatin, Taxol, parapl | Nanjing NingQi Medicine Science and Technology Co., Ltd. | Non-small Cell Lung Cancer | 11/17 | | | |
NCT03092986: Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer |
|
|
| Completed | 4 | 60 | RoW | Paclitaxel, Xelpac, Carboplatin, carboplat, Cisplatin, Platinex, Vinblastine Sulfate, Velvin, three dimensional conformal radiotherapy | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Carcinoma, Non-Small-Cell Lung | 06/18 | 12/18 | | |
ChiCTR1800015752: Dose-exploration study of LBPcombined with paclitaxel in the treatment of platinum-sensitive recurrent epithelial ovarian cancer |
|
|
| Recruiting | 4 | 30 | | LBP | Chongqing Cancer Hospital; Level of the institution：, Hainan Changan International Pharmaceutical Co., Ltd. | Ovarian cancer | | | | |
2017-003535-11: A study that investigates whether ranitidine has a added value in the prevention of paclitaxel-induced allergic reactions Een studie waarin wordt onderzocht of ranitidine een toegevoegde waarde heeft in het voorkomen van allergische reacties op paclitaxel. |
|
|
| Not yet recruiting | 4 | 554 | Europe | Ranitidine, Solution for injection, Zantac | Erasmus MC, Maasstad Hospital, Erasmus MC, Maasstad Hospital, Erasmus mc | Paclitaxel-induced hypersensitivity reactions Overgevoeligheidsreacties ontstaan door paclitaxel, Hypersensitivity reactions as a result of paclitaxel administration Overgevoeligheidsreacties als een gevolg van paclitaxel toediening, Body processes [G] - Immune system processes [G12] | | | | |
ChiCTR-IPR-17010455: Phase II exemestane versus paclitaxel as first-line treatment of patients with metastatic hormone receptor positive breast cancer |
|
|
| Recruiting | 4 | 260 | | exemestane ;paclitaxel | Department of Breast Medical Oncology, Beijing Cancer Hospital; Beijing Cancer Hospital, Pfizer investment co., LTD | breast cancer | | | | |
NCT03550482: Oncoxin® and Quality of Life in Cancer Patients |
|
|
| Completed | 4 | 133 | RoW | ONCOXIN® | Catalysis SL | Gastric Cancer Stage II, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III, Gastric Cancer Stage III | 03/19 | 05/19 | | |
ChiCTR1800015494: Clinical study of apatinib mesylate tablets combined with chemotherapy in the treatment of platinum sensitive recurrent ovarian cancer |
|
|
| Recruiting | 4 | 60 | | To use Apatinib mesylate tablets，and Paclitaxel and carboplatin ;Only use Paclitaxel and carboplatin | Jiangsu Cancer Hospital; Jiangsu Hengrui pharmaceutical Limited by Share Ltd, Self financing | Oophoroma | | | | |
ChiCTR-IPR-15006245: A clinical studies of concurrent chemoradiotherapy after Pemetrexed and cisplatin or Paclitaxel and cisplatin in stage IIIA/B Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 4 | 150 | | Pemetrexed+cisplatin(2 cycles) followed by Alimta+cisplatin(2 cycles)+concurren thoracic irradiation ;Paclitaxel+cisplatin(2 cycles) followed by Paclitaxel+cisplatin+concurrent thoracic irradiation | GuangZhou Istitute Of Respiratory Disease; GuangZhou Istitute Of Respiratory Disease, Self-financing | Non-small Cell Lung Cance | | | | |
ChiCTR1800016272: Randomized controlled multicenter trial of neo adjunvant chemotherapy with combination chemotherapy of LBP orparaplatin plus paclitaxel in the treatment of stage II / III three negative breast cancer |
|
|
| Recruiting | 4 | 360 | | LBP combined with taxino ;Carboplatin and paclitaxel | Fourth Hospital of Hebei Medical Uniwersity Tumor Hospital of Hebei Province; Level of the institution：, Guizhou Yibai pharmaceutical Co.,Ltd | Triple Negative Breast Cancer | | | | |
ChiCTR1900021983: Clinical observation of liposomal paclitaxel combined with Anlotinib Hydrochloride in patients with SCLC after first-line standard chemotherapy |
|
|
| Not yet recruiting | 4 | 30 | | liposomal paclitaxel combined with Anlotinib Hydrochloride | Shandong Provincial Cancer Hospital affiliated to Shandong University; Shandong Provincial Cancer Hospital affiliated to Shandong University, no | Small Cell Lung Cancer | | | | |
ChiCTR2000040783: Study on the construction of tumor precision medication patterns - non small cell lung cancer TP regimen as an example |
|
|
| Completed | 4 | 60 | | With chemotherapy regimen of paclitaxel and cisplatin. | Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital, Chinese Academy of Medical Sciences | Lung Cancer | | | | |
| Recruiting | 4 | 30 | | Apatinib, 250 mg qd, po; standard chemotherapy | Daping Hospital; Daping Hospital, self-financing | ovarian cancer | | | | |
| Recruiting | 4 | 40 | | Apatinib, 250 mg Po qd, paclitaxel or docetaxel combined with platinum standard chemotherapy regimens, q21d, 2 to 6 cycles of chemotherapy ;paclitaxel or docetaxel combined with platinum standard chemotherapy regimens, | Daping Hospital; None, self-financing | esophageal cancer | | | | |
ChiCTR1800016222: The Clinical study of PLD plus trastuzumab and paclitaxel as neoadjuvant therapy for HER2 positive breast cancer |
|
|
| Recruiting | 4 | 50 | | PLD combined with trastuzumab and paclitaxel | Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences, Self financing | breast cancer | | | | |
ChiCTR-IPR-17012201: An Open-label, Randomized Controlled Clinical Study: Neoadjuvant Chemotherapy using Paclitaxel Liposomes in Combination With Tegafur Verus Oxaliplatin Combination With Tegafur in Local Advanced Gastric Cancer |
|
|
| Recruiting | 4 | 192 | | Paclitaxel Liposomes +Tegafur ;Oxaliplatin + Tegafur | the First affiliated Hospital of Guangxi Medical University; the First affiliated Hospital of Guangxi Medical University, self-finacing | Gastric Cancer | | | | |
ChiCTR1800017225: Clinical study of apatinib mesylate combined with paclitaxel in second-line and second-line maintenance of advanced gastric cancer |
|
|
| Recruiting | 4 | 60 | | apatinib mesylate combined with paclitaxel | Jiangxi Tumor Hospital; Jiangxi Tumor Hospital, Jiangsu hengrui pharmaceutical co. LTD | gastric cancer | | | | |
ChiCTR1800019090: A study for intraperitoneal and intravenous paclitaxel plus apatinib and S-1 conversion therapy for gastric cancer with positive exfoliative cancer cells |
|
|
| Recruiting | 4 | 36 | | intraperitoneal and intravenous paclitaxel plus apatinib and S-1 | Fourth Hospital of Hebei Medical University; None, self-raised | gastric cancer | | | | |
ChiCTR1900026893: Efficacy and safety of paclitaxel (albumin-binding) combined with carboplatin for neoadjuvant therapy for unresectable ovarian cancer in women: a single-center, open, one-arm, phase Ib, and phase II clinical study |
|
|
| Recruiting | 4 | 54 | | paclitaxel (albumin-binding) combined with carboplatin | Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, CSPC Ouyi Pharmaceutical Co., Ltd. | ovarian cancer | | | | |
ChiCTR1800020449: A prospective, multicenter clinical study for pyrrotinib combined with herceptin plus paclitaxel combined with cisplatin in the preoperative treatment of her2-positive breast cancer |
|
|
| Not yet recruiting | 4 | 40 | | pyrrotinib combined with trastuzumab plus paclitaxel combined with cisplatin | Breast center of Jiangxi Tumor Hospital; None, Self financing | breast cancer | | | | |
ChiCTR1900024987: A randomized, controlled, multi-center clinical study for the efficacy and safety of lobaplatin combined with paclitaxel plus cisplatin plus paclitaxel in the treatment of locally advanced esophageal squamous cell carcinoma |
|
|
| Recruiting | 4 | 384 | | PTX and LBP ;PTX and DDP | Cancer Hospital Chinese Academy of Medical Sciences; Yunnan Cancer Hospital; The Fourth Hospital of Hebei Medical University; Cancer Hospital Chinese Academy of Medical Sciences, Hainan Changan International Pharmaceutical Co., Ltd. | Esophagus Cancer | | | | |
ChiCTR1900024013: Paclitaxel for injection (albumin-bound) combined with carboplatin paclitaxel versus paclitaxel combined with carboplatin in the treatment of epithelial ovarian cancer: an open, multicenter clinical study. |
|
|
| Not yet recruiting | 4 | 100 | | Paclitaxel for injection (albumin binding)260mg/m2 ivgtt d1; Carboplatin injection AUC 5 ivgtt d1; 21 days in one cycle, 6 cycles in total. ;Paclitaxel 175mg/m2 ivgtt d1; Carboplatin injection AUC 5 ivgtt d1; 21 days in one cycle, 6 cycles in total | Fourth Hospital of Hebei Medical University; Fourth Hospital of Hebei Medical University, CSPC Ouyi Pharmaceutical Co., Ltd. | ovarian cancer | | | | |
ChiCTR1900023675: Multicenter randomized controlled study for rmhTNF versus paclitaxel intraperitoneal infusion in the treatment of peritoneal metastasis of gastric cancer |
|
|
| Not yet recruiting | 4 | 183 | | Peritoneal exploration + rmhTNF intraperitoneal perfusion for 2 times + 6 cycles of systemic chemotherapy ;Peritoneal exploration + paclitaxel intraperitoneal perfusion for 1 time + 6 cycles of systemic chemotherapy ;Peritoneal exploration + rmhTNF intraperitoneal perfusion for 2 times + paclitaxel intraperitoneal perfusion for 1 time + systemic chemotherapy for 6 cycles | Beijing Cancer Hospital; Beijing Cancer Hospital, Shanghai Weike Biopharmaceutical Co., Ltd | Peritoneal metastasis of gastric cancer | | | | |
NCT02419742: Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen |
|
|
| Completed | 4 | 110 | RoW | Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Paclitaxel, Trastuzumab | Hoffmann-La Roche | Breast Cancer | 06/21 | 06/21 | | |
ChiCTR2000038555: A randomized controlled trial for the efficacy and side effects of paclitaxel liposomes compared with paclitaxel in first-line chemotherapy for ovarian cancer |
|
|
| Recruiting | 4 | 600 | | Day1：paclitaxel (PTX) 175mg/m2 (according to the specific circumstances of drug dose adjustment range <=5%), continuous intravenous infusion 3H; Day1 or Day2：carboplatin (AUC=5), intravenous drip. ;Day1：paclitaxel liposome (Liposomal paclitaxel) 175mg/m2 (according to the specific circumstances of drug dose adjustment range <=5%), continuous intravenous infusion 3H; Day1 or Day2：carboplatin (AUC=5), intravenous drip. | Chongqing Cancer Hospital; Chongqing cancer hospital, National Center for Biotechnology Development, Ministry of Science and Technology of China | ovarian cancer | | | | |
ChiCTR1900026679: The influences of paclitaxel, calcitriol and cinacalcet on hemodialysis patients with CKD-MBD in real-world |
|
|
| Not yet recruiting | 4 | 1000 | | take paricalcitol according to the condition ;take calcitriol according to the condition ;take cinacalcet according to the condition | Changzhou second people's Hospital; Changzhou Second People's Hospital, self-raised | chronic kidney disease-mineral and bone disorder | | | | |
ChiCTR1900024319: A Clinical Study on the Benefit of Kanglaite Injection for the Survival of Advanced Non-small Cell Lung Cancer |
|
|
| Suspended | 4 | 334 | | Kanglaite Injection+Pemetrexed/Gemcitabine/Paclitaxel+Platinum ;Pemetrexed/Gemcitabine/Paclitaxel+Platinum | Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences; Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, National Key R&D Program, Key Speciality of Modernization of Traditional Chinese Medicine 2018；Zhejiang Kanglaite Pharmaceutical Co., Ltd. | non-small-cell lung cancer | | | | |
ChiCTR2100041782: Clinical study of Apatinib combined with paclitaxel in the treatment of gastric cancer |
|
|
| Recruiting | 4 | 40 | | Methanesulfonate Apatinib and paclitaxel. | Hubei Cancer Hospital; Hubei Cancer Hospital, raise independently | gastric cancer | | | | |
ChiCTR2000034491: Paclitaxel for Injection (Albumin-bound) in Combination with Carboplatin for First-Line Chemotherapy of Ovarian Cancer: a Multicenter, Open-Label, Single-Arm Clinical Study |
|
|
| Recruiting | 4 | 166 | | Paclitaxel for injection (albumin bound) 260 mg/m2, d1, Carboplatin injection AUC 5~6, d1, 21 days in one cycle, 6 cycles in total. | Medical University Affiliated Tumor Hospital; Medical University Affiliated Tumor Hospital, CSPC OUYI PHARMACEUTICAL CO., LTD. | ovarian cancer | | | | |
NCT03986528: Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 4 | 334 | RoW | Kanglaite Injection+Chemotherapy, Chemotherapy | Jie Li, Ministry of Science and Technology of the People´s Republic of China, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences | NSCLC | 03/22 | 05/22 | | |
ChiCTR2000040095: Exploratory clinical study of chemotherapy combined with Immune checkpoint inhibitors for locally advanced and distant metastatic penile cancer |
|
|
| Not yet recruiting | 4 | 15 | China | Albumin taxol + Cisplatin + Bleomycin+Tislelizumab Injection | Beijing Chaoyang Huanxing Cancer Hospital ; Beijing Chaoyang Huanxing Cancer Hospital, Beijing Medical Award Foundation, Baiji Shenzhou (Beijing) Biotechnology Co., LTD | Penile cancer | | | | |
2022-001107-41: Combined treatment of intraperitoneal chemotherapy after optimal interval surgery in advanced ovarian cancer Esquema combinado de quimioterapia intraperitoneal tras cirugía de intervalo óptimo en cáncer de ovario avanzado |
|
|
| Not yet recruiting | 4 | 20 | Europe | Cisplatino, Paclitaxel, Concentrate for solution for infusion, Cisplatino, Paclitaxel | Fundación para la Formación e Investigación Sanitarias de la Región de Murcia (FFIS), EVOMED | Ovarian cancer (OV-1) Cáncer de ovario (OV-1), Ovarian cancer (OV-1) Cáncer de ovario (OV-1), Diseases [C] - Cancer [C04] | | | | |
ChiCTR1900022560: A prospective, open-label, multicenter clinical study for the efficacy and safety of paclitaxel (albumin-binding) combined with AC chemotherapy in the treatment of postoperative breast cancer |
|
|
| Not yet recruiting | 4 | 400 | | Paclitaxel (albumin-bound) + anthracycline + cyclophosphamide | Chongqing Three Gorges Central Hospital; Chongqing Three Gorges Central Hospital, Jiangsu hengrui pharmaceutical co. LTD | Breast cancer | | | | |
NCT03096418: Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response |
|
|
| Recruiting | 4 | 50 | US | Paclitaxel, Taxol | University of Wisconsin, Madison, National Cancer Institute (NCI) | Breast Neoplasm Female | 06/26 | 06/26 | | |
NCT04217096: Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients |
|
|
| Not yet recruiting | 4 | 40 | RoW | Paclitaxel liposome, S-1 | Fudan University | Advanced Pancreatic Cancer | 09/22 | 03/23 | | |
ChiCTR1900024400: Paclitaxel for injection (albumin-bound) combined with carboplatin in the treatment of epithelial ovarian cancer: a single-arm, open, multicenter clinical study. |
|
|
| Recruiting | 4 | 100 | | Paclitaxel for injection (albumin binding) 260mg/m2, d1, Carboplatin injection AUC 5, d1, 21 days in one cycle, 6 cycles in total. | Fourth Hospital of Hebei Medical University; Fourth Hospital of Hebei Medical University, CSPC Ouyi Pharmaceutical Co., Ltd. | ovarian cancer | | | | |
ChiCTR1800019995: A Clinical Study for the Efficacy and Safety of Apatinib Combined with Gemcitabine plus Paclitaxel in Patients with Advanced Hepatosarcomatoid Carcinoma |
|
|
| Not yet recruiting | 4 | 40 | | Apatinib 250mg, po, qd+Gemcitabine, iv, d1, d8+Paclitaxel, iv, d1 | First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Zhengzhou University, Self-pay | Advanced Hepatosarcomatoid Carcinoma | | | | |
ChiCTR-ONC-11001927: Clinical observation of paclitaxel/ cisplatin concomitant chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma |
|
|
| Completed | 4 | 98 | | chemoradiotherapy (1) | The Affiliated Hospital of Guangdong Medical College; The Affiliated Hospital of Guangdong Medical College, Graduate student research funds | locoregionally advanced nasopharyngeal carcinoma | | | | |
ChiCTR2000038940: A multi-center clinical study of paclitaxel for injection (albumin-bound) in the treatment of patients with upper gastrointestinal tumor dystrophy |
|
|
| Recruiting | 4 | 240 | | nutrition management | Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital, Own expense | upper gastrointestinal tumor | | | | |
ChiCTR2100049365: Open versus controlled clinical study of Paclitaxel for injection (albumin bound) different administration regimens combined with gemcitabine in adjuvant treatment of resectable pancreatic cancer |
|
|
| Not yet recruiting | 4 | 90 | | Paclitaxel for injection (albumin-bound) 120mg/m^2, I.V., D1, D15, gemcitabine 1000mg/m^2, I.V., D1, D15, Q4w, 6 cycles. ;Paclitaxel for injection (albumin-bound) 120mg/m^2, I.V., D1, D8, gemcitabine 1000mg/m^2, I.V., D1, D8, Q3w, 6-8 cycles. ;Gemcitabine 1000mg/m^2, I.v.,.d1, D8, and sergio 60~100mg/d orally, twice a day, D1 ~14, Q3w, 6-8 cycles | Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University, Jiangsu Hengrui Pharmaceutical Co.,Ltd | pancreatic cancer | | | | |
ChiCTR2000033819: SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-Line Therapy in Patients With Pancreatic Adenocarcinoma With Synchronous Liver Metastases |
|
|
| Not yet recruiting | 4 | 50 | | PD-1+AG | RuiJin Hospital Ethics Committee Shanghai Jiaotong University School of Medicine; RuiJin Hospital Ethics Committee Shanghai JiaoTong University School of Medicine, Jiangsu Hengrui Pharmaceutical Co. Ltd. | Liver metastasis of pancreatic cancer | | | | |
ChiCTR2000040918: Objective to explore the effects of human body composition on the pharmacokinetics and toxicity of Paclitaxel-albumin in northern China |
|
|
| Recruiting | 4 | 80 | | Paclitaxel-albumin was infused within 30 minutes after the start of the infusion | Ordos Central Hospital, Inner mongolia; Ordos Central Hospital, Inner mongolia, Innovation plan of postgraduate education in Inner Mongolia Autonomous Region (Research and innovation projects for Postgraduates) | Malignant tumor | | | | |
KEYNOTE-B10, NCT04489888: A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) |
|
|
| Completed | 4 | 101 | Canada, US, RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Carboplatin, PARAPLATIN®, Paclitaxel, TAXOL®, ONXAL® | Merck Sharp & Dohme LLC | Squamous Cell Carcinoma of Head and Neck | 02/23 | 06/24 | | |
PADMA, NCT03355157 / 2016-004482-89: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - Study). |
|
|
| Completed | 4 | 130 | Europe | Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen) | German Breast Group, Pfizer, AMS Advanced Medical Services GmbH | Metastatic Breast Cancer | 08/24 | 08/24 | | |
AIRE, NCT05033769: Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer |
|
|
| Recruiting | 4 | 82 | Europe | Eribulin Injection [Halaven], Eribulin, Paclitaxel injection, Paclitaxel | Institut fuer Frauengesundheit, Eisai GmbH | Breast Cancer Female, Neoplasm, Breast, Breast Cancer Metastatic | 07/23 | 09/23 | | |
NCT05730777: Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics |
|
|
| Not yet recruiting | 4 | 200 | RoW | Bifidobacterium Bifidum Oral Capsule, Probiotics, Cisplatin, conventional antitumor treatmen, Carboplatin, Paclitaxel, Atlizumab | Peking University Third Hospital | Cancer Therapy-related Cardiovascular Toxicity | 07/23 | 12/23 | | |
ChiCTR2100046731: A prospective, single-center, observational real-world study: evaluating the efficacy of pembrolizumab combined with standard chemotherapy (cisplatin/carboplatin + paclitaxel) in the first-line treatment of locally recurring head and neck squamous cell carcinoma under different TP53 and PIK3CA states and safety |
|
|
| Recruiting | 4 | 80 | | Bolivizumab + standard chemotherapy (cisplatin/carboplatin + paclitaxel) ;Bolivizumab + standard chemotherapy (cisplatin/carboplatin + paclitaxel) ;Bolivizumab + standard chemotherapy (cisplatin/carboplatin + paclitaxel) ;Bolivizumab + standard chemotherapy (cisplatin/carboplatin + paclitaxel) | Beijing Tongren Hospital; Beijing Tongren Hospital, Subject research | Head and neck squamous cell carcinoma | | | | |
ChiCTR2200062251: An exploratory study on the neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma with carrelizumab combined with chemotherapy |
|
|
| Not yet recruiting | 4 | 30 | | Carrelizumab + carboplatin + paclitaxel | Provincial Hospital Affiliated to Shandong First Medical University; Provincial Hospital Affiliated to Shandong First Medical University, self-funded | esophageal cancer | | | | |
ChiCTR2000035178: Hepatic Artery Chemoembolization Sequential Apatinib in the Treatment of Advanced Hilar Cholangiocarcinoma: A One-arm, Exploratory, Open Clinical Study |
|
|
| Recruiting | 4 | 41 | | Paclitaxel (180mg / m2) and gemcitabine (1000mg / m2) were used during TACE, once every 4-6 weeks. Apatinib mesylate tablets were orally administered 5 days after operation, 250 mg, QD. | Department of Interventional medicine, the First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, self-financing | Advanced Hilar Cholangiocarcinoma | | | | |
TINES, NCT05603065: Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 4 | 32 | RoW | Tislelizumab + cisplatin + paclitaxel, Tislelizumab + radiotherapy | First Affiliated Hospital Xi'an Jiaotong University | Esophageal Squamous Cell Carcinoma | 10/23 | 10/24 | | |
ChiCTR2000032702: Efficacy and safety of Paclitaxel (Albumin-bound) combined with Oxaliplatin and S-1 in preoperative adjuvant treatment of gastric cancer |
|
|
| Recruiting | 4 | 70 | | Paclitaxel(Albumin-bound) | Gansu Provincial Hospital; Gansu Provincial Hospital, Self-raising | Gastric cancer | | | | |
ChiCTR2000039654: An exploratory, open, clinical study comparing carrelizumab combined with standard radiotherapy and chemotherapy with placebo combined with standard radiotherapy and chemotherapy in the adjuvant treatment of esophageal cancer after surgery |
|
|
| Recruiting | 4 | 50 | | Paclitaxel (135-175 mg/m2) + nedaplatin (80 mg/m2)/cisplatin (75~100mg/m2) or carboplatin (AUC=5~7) + carrelizumab (200 mg) , Simultaneous or sequential radiotherap ;Paclitaxel (135-175 mg/m2) + nedaplatin (80 mg/m2)/cisplatin (75~100mg/m2) or carboplatin (AUC=5~7) +placebo, simultaneous or sequential radiotherap. | The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, Self-funded | Postoperative T2~4N1~2M0 stage esophageal cancer | | | | |
| Recruiting | 4 | 34 | US | Optilume Urethral DCB | Urotronic Inc., Laborie Medical Technologies Inc. | Urethral Stricture | 09/25 | 03/26 | | |
NCT05183126: Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer |
|
|
| Recruiting | 4 | 22 | US | Paclitaxel, Taxol | University of Michigan Rogel Cancer Center | Breast Cancer | 11/24 | 11/24 | | |
ChiCTR2000035367: Precision neoadjuvant immunotherapy for local advanced non-small cell lung cancer with driver gene mutation negative |
|
|
| Completed | 4 | 100 | | Neoadjuvant therapy stage: Sintilimab antibody 200mg, q3w, 3 weeks per cycle, 2-4 cycles, then receive chest CT evaluation. Surgical treatment stage: the patients who have a response to targeting therapy (CR+PR) and the patients who have no response to targeting therapy but can still receive surgical treatment.Surgical treatment stage: the patients who have a response to targeting therapy (CR+PR) and the patients who have no response to targeting therapy but can still receive surgical treatment.Adjuvant therapy stage: all resectable patient will receive adjuvant therapy according to the NCCN guidelines. The therapy regimens for the unresectable patients will be made according to the NCCN guidelines.; Neoadjuvant therapy stage: sintilimab 200mg, q3w, 3 weeks per cycle, 2-4 cycles; bevacizumab, 3 weeks per cycle, 2-4 cycles, then receive chest CT evaluation. Surgical treatment stage: the patients who have a response to targeting therapy (CR+PR) and the patients who have no response to targeting therapy but can still receive surgical treatment.Adjuvant therapy stage: all resectable patient will receive adjuvant therapy according to the NCCN guidelines. The therapy regimens for the unresectable patients will be made according to the NCCN guidelines.; Neoadjuvant therapy stage: PD-1 antibody 200mg, q3w, 3 weeks per cycle, 2-4 cycles; Platinum-based chemotherapy (squamous: carboplatin AUC5, paclitaxel 200mg/m2 or gemcitabine 1000mg/m2; non-squamous: carboplatin AUC5, pemetrexed 500mg/m2), 3 weeks per cycle, 2-4 cycles, then receive chest CT evaluation.Surgical treatment stage: the patients who have a response to targeting therapy (CR+PR) and the patients who have no response to targeting therapy but can still receive surgical treatment.Adjuvant therapy stage: all resectable patient will receive adjuvant therapy according to the NCCN guidelines. The therapy regimens for the unresectable patients will be made according to the NCCN guidelines. | Department of Thoracic Surgery, Shanghai Pulmonary Hospital; Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Shanghai Hospital Development Center | Non-small cell lung cancer | | | | |
ChiCTR2300069672: Phase II clinical study on the first-line treatment of advanced gastric and gastroesophageal junction adenocarcinoma with Camrelizumab combined with albumin-binding paclitaxel and S-1 |
|
|
| Recruiting | 4 | 46 | | Camrelizumab+albumin-binding paclitaxel+S-1 | Henan Cancer Hospital ; Henan Cancer Hospital, At one's own expense | Adenocarcinoma of stomach and gastroesophageal junction | | | | |
ChiCTR2100051903: Neoadjuvant camrelizumab (PD-1 inhibitors) plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients |
|
|
| Not yet recruiting | 4 | 16 | | 2 cycles of neoadjuvant therapy (including 2 doses of camrelizumab, 2 cycles of paclitaxel, and carboplatin) | Daqing Oilfield General Hospital; Daqing Oilfield General Hospital, None | locally advanced esophageal squamous cell carcinoma | | | | |
VIGOR, NCT05583188: Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC |
|
|
| Terminated | 4 | 5 | US | Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Carboplatinum, Cipsplatin, Pemetrexed, Gemcitabine, Paclitaxel, Standard of care neoadjuvant therapy, Vinorelbine, Surgical Resection | Galvanize Therapeutics, Inc. | NSCLC | 02/24 | 03/24 | | |
ChiCTR2100042088: Recombinant Human Endostatin Combined With Platinum-Containing Dual Drug for the First-Line Treatment of Driver Gene-Negative Advanced Non-Small Cell Lung Cancer: a Multicenter, Single-Arm Trial |
|
|
| Recruiting | 4 | 100 | | Endostar (210mg, durative transfused for 120 hours) was administered every three weeks beginning on the first day of each treatment cycle. Carboplatin (AUC 5-6) or cisplatin (75mg/m2)+pemetrexed (500 mg/m2) Q3W with 4 cycles, followed by Endostar+ pemetrexed at the end of 4 cycles until disease progression or i ;Endostar (210mg, durative transfused for 120 hours) was administered every three weeks beginning on the first day of each treatment cycle. Carboplatin(AUC 5-6) or cisplatin (75 mg/m2)+Paclitaxel (175 mg/m2) Q3W with 4 cycles, followed by Endostar at the end of 4 cycles until disease progression or intolerable t | The First Affiliated Hospital of Shandong First Medical University; The First Affiliated Hospital of Shandong First Medical University, Self-financing | Advanced Non-small Cell Lung Cancer | | | | |
COMPASS, NCT03164980: Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer |
|
|
| Completed | 4 | 89 | Europe | Trabectidin (Yondelis) | North Eastern German Society of Gynaecological Oncology, Frankfurter Institut für Klinische Krebsforschung IKF GmbH, PharmaMar | Quality of Life, Ovarian Cancer, Recurrent Ovarian Carcinoma | 08/23 | 08/23 | | |
NCT03794778: Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer |
|
|
| Active, not recruiting | 4 | 396 | RoW | pegylated liposomal doxorubicin, duomeisu, paclitaxel, zishanchun, Carboplatin, kabo | Women's Hospital School Of Medicine Zhejiang University | Efficacy and Safety | 03/24 | 03/24 | | |
ChiCTR2200060739: Neoadjuvant chemotherapy combined with fluzoparil in the treatment of BRCA germline mutations with triple-negtive breast cancer: an open, multicenter, cohort clinical study |
|
|
| Not yet recruiting | 4 | 60 | | Fluzoparil+Paclitaxel (5-8 cycle, 4 cycles) ;Fluzoparil+Paclitaxel (3-8 cycle, 6 cycles) | Jiangsu Province Hospital; Jiangsu Province Hospital, Self-raised | triple-negative breast cancer | | | | |
ChiCTR2100052825: Phase II clinical studies of single center, open, single arm of paclitaxel (albumin binding) in combination with camrelizumab second line and above line treatment of metastatic/locally unresectable soft tissue sarcoma |
|
|
| Not yet recruiting | 4 | 40 | | Camrelizumab and chemotherapy | He'nan Tumor Hospital; He'nan Tumor Hospital, Self-funded | Soft tissue sarcoma | | | | |
ChiCTR1900021783: A study for apatinib combined with platinum/paclitaxel as neoadjuvant chemotherapy for esophageal cancer |
|
|
| Recruiting | 4 | 39 | | Apatinib combined with Paclitaxel injection and Cisplatin | Anyang City Oncology Hospital; Anyang City Oncology Hospital, None | Esophageal Cancer | | | | |
NCT03270007: Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy |
|
|
| Recruiting | 4 | 304 | RoW | Vinorelbine, Intensive treatment | Tao OUYANG | Primary Breast Cancer | 06/24 | 12/24 | | |
ChiCTR2100046837: Single-arm, prospective, open clinical study of Camrelizumab combined with albumin-binding paclitaxel and carboplatin in the treatment of advanced triple-negative breast cancer |
|
|
| Recruiting | 4 | 29 | | Camrelizumab combined with chemotherapy | Henan Tumor Hospital; Henan Tumor Hospital, self-supporting | Triple Negative Breast Cancer | | | | |
ChiCTR2300068672: Efficacy and safety of Zimberelimab combined with Androtinib and chemotherapy in the treatment of recurrence/metastasis HNSCC. |
|
|
| Recruiting | 4 | 20 | | Zimberelimab combine with Androtinib + Paclitaxel-albumin + Cisplatin/Carboplatin | Beijing Chaoyang Sanhuan Cancer Hospital; Beijing Chaoyang Sanhuan Cancer Hospital, Not yet | Head and neck squamous cell carcinoma | | | | |
| Active, not recruiting | 4 | 400 | Europe | Bevacizumab, Avastin, Paclitaxel, Carboplatin | National Cancer Institute, Naples, Mario Negri Institute for Pharmacological Research | Ovarian Cancer | 12/24 | 12/24 | | |
|
ChiCTR2100054374: Exploratory clinical study on neoadjuvant therapy (Anlotinib combined chemotherapy) in patients with esophageal malignant tumor |
|
|
| Not yet recruiting | 4 | 31 | | Angotini + paclitaxel + cisplatin | Henan Provincial Chest Hospital; Henan Provincial Chest Hospital, Henan Provincial Health Commission | Esophageal malignant tumor | | | | |
ChiCTR2200067160: Efficacy of neoadjuvant versus adjuvant immunotherapy in stage II-IIIA resectable non-small cell lung cancer |
|
|
| Not yet recruiting | 4 | 50 | | Parbolizumab 200 mg + paclitaxel 200 mg/m2 (or other agents indicated by genetic testing) + carboplatin AUC 6 IV Q3W × 4 cycle ;Direct operation: after operation, pabolizumab 200 mg + paclitaxel 200 mg/m2 (or other drugs indicated by gene testing) + carboplatin AUC 6 IV Q3W × 4 cycles, continue to maintain 200 mg of pabolizumab until 1 year after operation | Peking Union Medical College Hospital; Peking Union Medical College Hospital, National High Level Hospital Clinical Research Funding (2022-PUMCH-B-012) | Non-small cell lung cancer | | | | |
ChiCTR2200057408: Efficacy and safety of triplizumab combined with gemcitabine and cisplatin in the treatment of urothelial cancer |
|
|
| Recruiting | 4 | 40 | China | triplizumab combined with paclitaxel ;triplizumab combined with paclitaxe ;triplizumab combined with paclitaxe ;triplizumab combined with paclitaxe | The Second Hospital of Tianjin Medical University ; The Second Hospital of Tianjin Medical University, tianjinshiqingnianrencaituojugongcheng | Urothelial carcinoma | | | | |
ChiCTR2300068870: Efficacy and safety of sintilimab combined with paclitaxel/cisplatin (TP) as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma (HNSCC) in a prospective real-world study |
|
|
| Not yet recruiting | 4 | 30 | | Sindillizumab :200mg, i.v., d1, q3w; Cisplatin 25 mg/m2, i.v.,d1-3,q3w Paclitaxel 75 mg/m2, i.v.,d1,q3w, Radical head and neck squamous cell carcinoma resection was evaluated by the investigators at 3-4 weeks after the completion of the second dose after 2 courses of treatment | Affiliated Hospital of Yanbian University; Affiliated Hospital of Yanbian University, raised by researchists | Locally advanced head and neck squamous cell carcinoma | | | | |
